5-fluoro-2-methyl-N-[5-(5H-pyrrolo[2,1-c][1,4]benzodiazepine-10(11H)-yl carbonyl)-2-pyridinyl]benzamide (CL-385004) and analogs as orally active arginine vasopressin receptor antagonists
Bioorganic & Medicinal Chemistry LettersPublished 1 July 1999Open access
Venkatesan Aranapakam, J. Donald Albright, G Grosu, Efren G. Delos Santos, Peter S. Chan, Joseph Coupet
Citations20
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
Synthesis and structure-activity relationships (SAR) of orally active arginine vasopressin (AVP) receptor antagonists are discussed.
Abstract
Synthesis and structure-activity relationships (SAR) of orally active arginine vasopressin (AVP) receptor antagonists are discussed. Potent and orally active AVP receptor antagonists are produced when ring A of VPA-985 (1) is replaced with a 3-pyridinyl unit (2b).
Keywords
MedicineBiochemistry, Genetics and Molecular Biology
British Journal of PharmacologyCharacterization of a novel aquaretic agent, OPC‐31260, as an orally effective, nonpeptide vasopressin V<sub>2</sub> receptor antagonist
347 Citations1992Yoshitaka Yamamura, Hidenori Ogawa +10 more
The results indicate that OPC‐31260 is a selective V2 receptor antagonist and behaves as an aquaretic agent that will be a useful tool in studying the physiological role of AVP and in the treatment of various conditions characterized by water retention.
Journal of Clinical InvestigationPotent aquaretic agent. A novel nonpeptide selective vasopressin 2 antagonist (OPC-31260) in men.
155 Citations1993Akihiro Ohnishi, Y Orita +6 more
OPC-31260 safely induced a potent aquaretic effect in men and increased plasma osmolality and plasma Na slightly, but did not alter plasma K, blood pressure, or heart rate.
Journal of Medicinal Chemistry5-Fluoro-2-methyl-<i>N</i>-[4-(5<i>H</i>-pyrrolo[2,1-<i>c</i>]- [1,4]benzodiazepin-10(11<i>H</i>)-ylcarbonyl)-3- chlorophenyl]benzamide (VPA-985): An Orally Active Arginine Vasopressin Antagonist with Selectivity for V<sub>2</sub>Receptors
148 Citations1998J. Donald Albright, Marvin F. Reich +9 more
Regulatory PeptidesSignal transduction of V1-vascular vasopressin receptors
130 Citations1992Marc Thibonnier
This review covers the recent developments gained in the exploration of V1-vascular vasopressin (AVP) receptors and examines the different radioligands available for the pharmacological characterization of these receptors.
Journal of Medicinal ChemistryOrally Active, Nonpeptide Vasopressin V<sub>2</sub> Receptor Antagonists: A Novel Series of 1-[4-(Benzoylamino)benzoyl]-2,3,4,5-tetrahydro-1<i>H</i>-benzazepines and Related Compounds
87 Citations1996Hidenori Ogawa, Hiroshi Yamashita +11 more
A novel series of nonpeptide vasopressin V2 receptor antagonists that show a high affinity for V2 (and V1a) receptors and compounds with an alkylamino group on the benzazepine ring have been shown to have oral activity.
Current Pharmaceutical DesignRecent Advances in the Discovery and Development of Vasopressin Antagonists: Peptide and Nonpeptide Vta and V2 Receptor Antagonists
30 Citations1997J. Donald Albright, Peter S. Chan
This review covers the characterization of vasopressin receptors V la, V2 and V3 (V1 b) (function, cloning, species variations, molecular modeling) and the discovery of non-peptide small molecules (of diverse structural types) that are potent AVP receptor antagonists.
Journal of Medicinal ChemistryDerivatives of 11-(1-piperazinyl)-5H-pyrrolo[2,1-c][1,4]benzodiazepine as central nervous system agents
21 Citations1980William B. Wright, Eugene N. Greenblatt +3 more
The most interesting compound, 11-(1-piperazinyl)-5H-pyrrolo[2,1-c][1,4]benzodiazepine, showed dual activity as an antidepressant against tetrabenazine depression and as a neuroleptic as measured by protection vs. amphetamine lethality in grouped mice.